Learning Objectives:

  1. To describe the biological rationale for mild therapeutic hypothermia following global cerebral ischemia
  2. To understand the motivation for the ICECAP design and how it helps us answer an important clinical question
  3. Be familiar with current progress of the trial
  4. Put ICECAP into context of other recent clinical trials
Session date: 
01/06/2022 - 7:30am to 8:30am CST
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
William Meurer, MD